Prognostic value of statins and beta-blockers in ovarian cancer
(2022)
Files
ThesisAlexandraCouttenier.pdf
Restricted Access - Adobe PDF
- 10.73 MB
Details
- Authors
- Supervisors
- Robert, Annie
- Abstract
- Despite improvement in cancer therapies, the prognosis of ovarian cancer remains quite poor with a relative 5-years survival of about 40% in European countries. Therefore, new treatment perspectives are required. One is to repurpose drugs to fight cancer. In this context, preclinical studies have shown that statins and 𝛽-blockers could be promising. In order to analyse if these two classes of drugs can improve ovarian cancer survival, we performed population-based studies, clinical series and meta-analyses. All results were consistent and showed that statin users had a better survival. For β-blockers, analyses were more complex because β-blockers are prescribed for various pathologies that can be potentially serious and impact survival. However, our results show that the survival of β-blockers users is, at least, not worse than that of nonusers. Therefore, statins and β-blockers should be continued after a diagnosis of ovarian cancer.
- Affiliations
Citations
Couttenier, A. (2022). Prognostic value of statins and beta-blockers in ovarian cancer. https://hdl.handle.net/2078.5/128064